{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:23:34Z","timestamp":1724855014560},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"DOI":"10.7759\/cureus.67318","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T16:50:36Z","timestamp":1724172636000},"source":"Crossref","is-referenced-by-count":0,"title":["CT-Guided Online Adaptive Hypofractionated Radiotherapy for Primary Bladder Cancer: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Ryan","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colton","family":"Ladbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borna","family":"Maraghechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savita","family":"Dandapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang SS","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, et al.. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017, 198:552-9. 10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.04.030","article-title":"Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes","volume":"74","author":"Bochner BH","year":"2018","unstructured":"Bochner BH, Dalbagni G, Marzouk KH, et al.. Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes. Eur Urol. 2018, 74:465-71. 10.1016\/j.eururo.2018.04.030","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011903.pub2","article-title":"Robotic versus open radical cystectomy for bladder cancer in adults","volume":"4","author":"Rai BP","year":"2019","unstructured":"Rai BP, Bondad J, Vasdev N, et al.. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst Rev. 2019, 4:CD011903. 10.1002\/14651858.CD011903.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh DJ","year":"2018","unstructured":"Parekh DJ, Reis IM, Castle EP, et al.. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018, 391:2525-36. 10.1016\/S0140-6736(18)30996-6","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel VG","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020, 70:404-23. 10.3322\/caac.21631","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta AR","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, et al.. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023, 24:669-81. 10.1016\/S1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak RH","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, et al.. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014, 32:3801-9. 10.1200\/JCO.2014.57.5548","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury A","year":"2021","unstructured":"Choudhury A, Porta N, Hall E, et al.. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021, 22:246-55. 10.1016\/S1470-2045(20)30607-0","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman AL","year":"2003","unstructured":"Zietman AL, Sacco D, Skowronski U, et al.. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003, 170:1772-6. 10.1097\/01.ju.0000093721.23249.c3","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak KS","year":"2016","unstructured":"Mak KS, Smith AB, Eidelman A, et al.. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016, 96:1028-36. 10.1016\/j.ijrobp.2016.08.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2014.09.016","article-title":"Defining bowel dose volume constraints for bladder radiotherapy treatment planning","volume":"27","author":"McDonald F","year":"2015","unstructured":"McDonald F, Waters R, Gulliford S, Hall E, James N, Huddart RA. Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol (R Coll Radiol). 2015, 27:22-9. 10.1016\/j.clon.2014.09.016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.06.061","article-title":"Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study","volume":"81","author":"Foroudi F","year":"2011","unstructured":"Foroudi F, Wong J, Kron T, et al.. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 2011, 81:765-71. 10.1016\/j.ijrobp.2010.06.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.02.011","article-title":"Adaptive radiotherapy in muscle invasive urinary bladder cancer--an effective method to reduce the irradiated bowel volume","volume":"99","author":"Tuomikoski L","year":"2011","unstructured":"Tuomikoski L, Collan J, Keyril\u00e4inen J, Visap\u00e4\u00e4 H, Saarilahti K, Tenhunen M. Adaptive radiotherapy in muscle invasive urinary bladder cancer--an effective method to reduce the irradiated bowel volume. Radiother Oncol. 2011, 99:61-6. 10.1016\/j.radonc.2011.02.011","journal-title":"Radiother Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy","volume":"10","author":"de Mol van Otterloo SR","year":"2020","unstructured":"de Mol van Otterloo SR, Christodouleas JP, Blezer EL, et al.. The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy. Front Oncol. 2020, 10:1328. 10.3389\/fonc.2020.01328","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041005","article-title":"Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance","volume":"10","author":"Hafeez S","year":"2020","unstructured":"Hafeez S, Webster A, Hansen VN, et al.. Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. BMJ Open. 2020, 10:e041005. 10.1136\/bmjopen-2020-041005","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James ND","year":"2012","unstructured":"James ND, Hussain SA, Hall E, et al.. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012, 366:1477-88. 10.1056\/NEJMoa1106106","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation","volume":"31","author":"Murthy V","year":"2019","unstructured":"Murthy V, Gupta P, Baruah K, et al.. Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation. Clin Oncol (R Coll Radiol). 2019, 31:646-52. 10.1016\/j.clon.2019.06.005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.09.010","article-title":"Clinical outcomes with dose-escalated adaptive radiation therapy for urinary bladder cancer: a prospective study","volume":"94","author":"Murthy V","year":"2016","unstructured":"Murthy V, Masodkar R, Kalyani N, et al.. Clinical outcomes with dose-escalated adaptive radiation therapy for urinary bladder cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2016, 94:60-6. 10.1016\/j.ijrobp.2015.09.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.291","article-title":"Phase I dose-escalated image-guided adaptive bladder radiotherapy study: results of first dose cohort (68Gy)","volume":"32","author":"Huddart R","year":"2014","unstructured":"Huddart R, McDonald F, Hafeez S, et al.. Phase I dose-escalated image-guided adaptive bladder radiotherapy study: results of first dose cohort (68Gy). J Clin Oncol. 2014, 32:291. 10.1200\/jco.2014.32.4_suppl.291","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.08.001","article-title":"A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer","volume":"30","author":"Yeh J","year":"2021","unstructured":"Yeh J, Bressel M, Tai KH, Kron T, Foroudi F. A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer. Clin Transl Radiat Oncol. 2021, 30:65-70. 10.1016\/j.ctro.2021.08.001","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281595-ct-guided-online-adaptive-hypofractionated-radiotherapy-for-primary-bladder-cancer-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T16:50:39Z","timestamp":1724172639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281595-ct-guided-online-adaptive-hypofractionated-radiotherapy-for-primary-bladder-cancer-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.67318","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}